CERo Therapeutics Phase 1 CER-1236 trial shows safety, 61-day transfusion-free interval; expands to MDS/MF

CERO THERAPEUTICS HOLDINGS, INC.

First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.
Second patient (MDS/AML) had 61-day platelet transfusion-free interval after CER-1236 treatment.
FDA amendment filed to include advanced MDS and myelofibrosis as additional cohorts.
Company to host analyst call on Jan 7, 2026 at 5:00 PM ET to discuss progress and strategy.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.